Nomura Healthcare Fund Class C DLHCX

Medalist Rating as of | See Nomura Investment Hub
  • NAV / 1-Day Return 23.46  /  +0.04 %
  • Total Assets 739.3M
  • Adj. Expense Ratio
    1.960%
  • Expense Ratio 1.960%
  • Distribution Fee Level Average
  • Share Class Type Level Load
  • Category Health
  • Investment Style Mid Value
  • Min. Initial Investment 1,000
  • Status Open
  • TTM Yield 1.82%
  • Turnover 4%

USD | NAV as of Oct 03, 2026 | 1-Day Return as of Oct 03, 2026, 12:11 AM GMT+0

Morningstar’s Analysis DLHCX

Will DLHCX outperform in the future?

Get our overall rating based on a fundamental assessment of the pillars below.

A mixed bag.

Senior Analyst William Samuel Rocco

William Samuel Rocco

Senior Analyst

Summary

Macquarie Healthcare’s pros and cons continue to offset each other, and the strategy retains its Average People and Process ratings.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings DLHCX

  • Current Portfolio Date
  • Equity Holdings —
  • Bond Holdings —
  • Other Holdings —
  • % Assets in Top 10 Holdings 38.4
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Pfizer Inc

4.41 34M
Healthcare

UCB SA

4.18 33M
Healthcare

AbbVie Inc

4.12 32M
Healthcare

Merck & Co Inc

4.08 32M
Healthcare

Gilead Sciences Inc

3.95 31M
Healthcare

Regeneron Pharmaceuticals Inc

3.90 30M
Healthcare

Eli Lilly and Co

3.86 30M
Healthcare

UnitedHealth Group Inc

3.50 27M
Healthcare

Sanofi SA

3.21 25M
Healthcare

Elevance Health Inc

3.18 25M
Healthcare

Sponsor Center